P
PriveBio develops precision therapeutics targeting metabolic dysfunction and fibro-inflammation in cardiorenal diseases, including obesity and chronic kidney disease, by utilizing human proteo-genomics data from extensive datasets. The company focuses on validated therapeutic targets to improve patient outcomes in these complex conditions.
Updated 4 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Product
Features
- PriveBio develops precision therapeutics targeting metabolic dysfunction and fibro-inflammation in cardiorenal diseases, including obesity and chronic kidney disease, by utilizing human proteo-genomics data from extensive datasets. The company focuses on validated therapeutic targets to improve patient outcomes in these complex conditions.